linjc16/ctgov huggingface dataset:
A Study Regarding Tissue Response During and After Treatment for Anal Cancer

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to improve the understanding for the tumour biology in relation to treatment response in patients with anal cancer by examining: The tumour microenvironment The localisation of and cellular interactions between the tumour and immune cells The gene and protein expression by cells present in the tumour and surrounding tissue.

Detailed Description
-----------------
All adult patients with anal cancer presenting within the Sahlgrenska University Hospital catchment area or treated at any time at Sahlgrenska University Hospital are eligible and will be asked to participate. The patients that are newly diagnosed or that have a suspected recurrence will be offered to enter the study with biopsies as well as blood samples during the diagnostic examination that is performed under anaesthesia. Biopsies will then be taken during follow-up exams if applicable. Biopsies will also be taken during surgery if that is scheduled and in cases where surgery is not necessary biopsies will be taken if the patient undergoes examinations under anaesthesia after treatment cessation. If it is not possible to take biopsies prior treatment blood samples will still be drawn.

Official Title
-----------------
ANCABio - a Study Regarding Tumour Microenvironment and the Predictive Capability of Biopsies From Anal Cancer in Predicting Response and Outcome

Conditions
-----------------
Anal Cancer

Intervention / Treatment
-----------------
* Other: Biopsies


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Newly diagnosed or recurrent anal cancer Exclusion Criteria: No diagnosis of anal cancer, contraindication to biopsies and blood samples

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Biopsies|Biopsies and blood samples will be taken at time of diagnosis or recurrence|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tumour micro environment | Evaluation of immuncell infiltrates in the tumour micro environment | 2024-2029 | 
| ctDNA | circulating tumour DNA | 2024-2029 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Anal cancer, Tumour micro environment, Chemoradiotherapy
Timing of Damage Control Orthopedic Surgery

Study Overview
=================
Brief Summary
-----------------
The decision to operate and surgical timing on multi-trauma patients remains controversial, inappropriate surgical timing may cause more complications which lead to poor prognosis. We hope to find out the connection between lactate and prognosis in multi-trauma patients, and the optimal timing of definitive treatment.

Detailed Description
-----------------
The decision to operate and surgical timing on multi-trauma patients remains controversial, inappropriate surgical timing may cause more complications which lead to poor prognosis. The aim of our study is to analyze if serum lactate a predictive factor of optimal surgical timing in multi-trauma patients. In order to obtain more accurate data, we choose to utilize ili database and trauma database instead of National Health Insurance Research Database. Multi-trauma patients from 2002 through 2022 were included to our study. We hope to find out the connection between lactate and prognosis in multi-trauma patients, and the optimal timing of definitive treatment.

Official Title
-----------------
Utilizing Dry Lab Database to Analyze the Prognostic Factors of Multi-trauma Patients and Determine the Optimal Timing of Definitive Orthopedic Operation

Conditions
-----------------
The Precision Personal Timeline in Definitive Surgery Associated With Outcome

Intervention / Treatment
-----------------
* Procedure: Utilizing dry lab database to analyze the prognostic factors of multi-trauma patients and determine the optimal timing of definitive orthopedic operation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: (1) Injury severity score(ISS) > 16 with pelvicfracture or long bone fracture requiring surgical fixation (2) Patient age ≥ 20. Pathologic fracture was excluded. Our primary endpoint si mortality rate, secondary endpoints include ICU stay, ICU complications (Sepsis, Pneumonia, Multiple organ failure) Exclusion Criteria: death before into undergoing surgery
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Utilizing dry lab database to analyze the prognostic factors of multi-trauma patients and determine the optimal timing of definitive orthopedic operation|to analyze if serum lactate a predictive factor of optimal surgical timing in multi-trauma patients. In order to obtain more accurate data, we choose to utilize ili database and trauma database instead of National Health Insurance Research Database.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| EQ5D5L | The functional outcome of daily activity | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
multi-trauma, lactate, definitive orthopedic operation
Effect of Spasticity on Tibial Nerve Entrapment

Study Overview
=================
Brief Summary
-----------------
Stroke is the most common cause of mortality and is one of the most common causes of morbidity in the world. Polyneuropathies and entrapment neuropathies are known as the complications of stroke

Official Title
-----------------
Impact of Lower Limb Spasticity on Tibial Nerve Entrapment in Patients With Stroke

Conditions
-----------------
Neuropathy, Stroke

Intervention / Treatment
-----------------
* Device: EMG


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1- A hundred patients with hemiplegia /paresis subsequent to a stroke as diagnosed by CT or MRI. 2- A hundred patients from both sexes, their ages ranged from (55-65) years. 3- Body weight of patients was ranged from(55 -95 kg) ,while their height was from (151-185 cm) and BMI was ranged from (20-30 kg/m2). 4- Duration of illness (6 - 9 months post stroke). 5- Patients have spasticity ranging from grade 1 to grade 3 according to modified Ashworth scale 6- Patients were medically stable Exclusion Criteria: 1- Patients with lumbosacral sciatica that could mimic TTS or interfere with its evaluation 2- Patients with tibial neuropathy, significant polyneuropathy, or marked orthopedic abnormalities; 3- Patients with contractures 4- Patients with psychological disturbance or seizures 5- Systemic diseases known to cause TTS, such as diabetes mellitus, hypothyroidism, rheumatoid arthritis, or chronic renal failure;

Ages Eligible for Study
-----------------
Minimum Age: 55 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group A<br> | Device: EMG<br>* Electrodiagnostic testing (electromyography and nerve conduction velocity) can objectively verify the tibial nerve dysfunction. Electrodiagnosis rests upon demonstrating impaired tibial nerve conduction across the tarsal tunnel in context of normal conduction<br>|
| Group B<br> | Device: EMG<br>* Electrodiagnostic testing (electromyography and nerve conduction velocity) can objectively verify the tibial nerve dysfunction. Electrodiagnosis rests upon demonstrating impaired tibial nerve conduction across the tarsal tunnel in context of normal conduction<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Electrodiagnostic testing | Electrodiagnostic testing (electromyography and nerve conduction velocity) can objectively verify the tibial nerve dysfunction. Electrodiagnosis rests upon demonstrating impaired tibial nerve conduction across the tarsal tunnel in context of normal conduction. Compression results in damage to the myelin sheath and manifests as delayed latencies and slowed conduction velocities | 30 minutes |
Retrospectively Analyze the Risk Factors of VTE in 5774 Patients With Thoracic Trauma From 33 Hospitals in China, and Established a Risk Prediction Model

Study Overview
=================
Brief Summary
-----------------
Retrospectively analyze the risk factors of VTE in 5774 patients with thoracic trauma from 33 hospitals in China, and established a risk prediction model

Detailed Description
-----------------
In order to explore the risk factors of VTE after acute thoracic trauma, we collected the diagnosis and treatment information of 5774 patients with thoracic trauma from 33 hospitals in China, retrospectively analyzed the risk factors of VTE in patients with thoracic trauma, and established a risk prediction model.

Official Title
-----------------
In Order to Explore the Risk Factors of VTE After Acute Thoracic Trauma, we Collected the Diagnosis and Treatment Information of 5774 Patients With Thoracic Trauma From 33 Hospitals in China, Retrospectively Analyzed the Risk Factors of VTE in Patients With Thoracic Trauma, and Established a Risk Prediction Model.

Conditions
-----------------
Thorax Injuries, Embolism Vein, Embolism, Pulmonary, Rib Fractures

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: admitted within three days of the chest trauma, VTE has not yet occurred, AIS score of thoracic injury was greater than or equal to 3, AIS score of other combined injuries was less than or equal to 2. Exclusion Criteria: received preventive physical or chemical anticoagulation before admission, VTE occurred before admission

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| VTE | venous thrombus embolism, including pulmonary embolism and deep vein thrombosis | Peri-treatment period | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
venous thrombus embolism, Thorax Injuries, risk factors, prediction model
Atrial Fibrillation Trial To Eliminate Risk-factors

Study Overview
=================
Brief Summary
-----------------
The goal of this prospective-enrolling cohort study is to test and observe the effect of an integrated multi-discipline care program in patients with atrial fibrillation. The main questions it aims to answer are: to understand the baseline characteristics and to explore the occult risk factors of the patients with AF; to monitor the treatment efficacy of the patients undergoing integrated care and potentially concur the clinical obstacles that prevent the best care for patients with AF. Participants will be treated by an integrated multi-discipline team that led by an electro-physiologist.

Detailed Description
-----------------
Atrial fibrillation (AF) is a heart condition that potentially leads to heart failure and ischemic stroke. The prevalence of AF is increasing due to aging population and improved treatment in other cardiovascular field. This study is to execute integrated multi-discipline care in a tertiary hospital, and to observe the effect and the obstacle that the program might ensue.

Official Title
-----------------
Atrial Fibrillation Trial To Eliminate Risk-factors

Conditions
-----------------
Atrial Fibrillation

Intervention / Treatment
-----------------
* Other: Integrated care


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: At least 20 years old, who have been diagnosed with atrial fibrillation by a cardiologist with an electrocardiogram Exclusion Criteria: Unable to complete the initial assessment and cooperate with the tracker Those who refuse to sign the subject's consent

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Integrated care|multi-discipline care program|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AF burden | The duration in AF on 14-day ECG monitor (percent) | 0 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MACE, major adverse cardiovascular event | ischemic heart disease with acute coronary syndrome, stroke (either ischemic or hemorrhagic stroke), cardiovascular death, and all-cause death | 0 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Atrial Fibrillation
Novel Approaches to Target MECOM/EVI1 in AML

Study Overview
=================
Brief Summary
-----------------
This is an academic, no-profit, multicenter, biological, non-pharmacologic study aimed at characterizing genome, transcriptome and proteome of patients affected by AML with MECOM or atypical 3q26 rearrangements.

Detailed Description
-----------------
This is an academic, no-profit, multicenter, biological, non-pharmacologic study aimed at characterizing genome, transcriptome and proteome of patients affected by AML with MECOM or atypical 3q26 rearrangements. To this end, BM samples and formalin fixed/paraffin-embedded BM biopsies will be collected at enrolment, before and after treatment, at relapse.

Official Title
-----------------
Novel Approaches to Target MECOM/EVI1 in Acute Myeloid Leukemia

Conditions
-----------------
AML, Adult

Intervention / Treatment
-----------------
* Biological: Biological characterization of AML with MECOM or atypical 3q26 rearrangements


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: AML with MECOM or atypical 3q26 rearrangements. Age ≥18. Signed written informed consent according to ICH/EU/GCP and national local laws. Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: Biological characterization of AML with MECOM or atypical 3q26 rearrangements|Peripheral blood and bone marrow withdrawal|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identification of MECOM/EVI1 regulators or downstream effectors potentially druggable | To assess the number of regulators or effectors of MECOM/EVI1 | At baseline |
Discovering Clinical Study Experiences of Patients With Pulmonary Hypertension

Study Overview
=================
Brief Summary
-----------------
Taking part in medical trials usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the completion of these specific demographic groups. This study will admit a wide range of data on the clinical trial experience of pulmonary hypertension patients to determine which factors prevail in limiting a patient's ability to join or finish a trial. It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future pulmonary hypertension patients.

Official Title
-----------------
Pulmonary Hypertension Clinical Trials: What Are Prevailing Patient Experiences in Pulmonary Hypertension Studies

Conditions
-----------------
Pulmonary Hypertension

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged ≥ 18 years old Able to comprehend the investigational nature of the protocol and provide informed consent Diagnosis of pulmonary hypertension Exclusion Criteria: No diagnosis of pulmonary hypertension confirmed Inability to perform regular electronic reporting Patient does not understand, sign, and return consent form

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients who decide to enroll in a pulmonary hypertension clinical research |  | 3 months | 
| Rate of patients who remain in pulmonary hypertension clinical research to trial completion |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pulmonary Hypertension
Free Fat Flap In Recurrent Neurogenic Thoracic Outlet Syndrome Surgical Treatment

Study Overview
=================
Brief Summary
-----------------
The Thoraco-Brachial Outlet Syndrome (T-BOS) corresponds to the entirety of clinical manifestations related to the compression of the branches of the brachial plexus and/or the subclavian vessels during their passage through the cervico-thoracic region. Following surgery, a recurrence of symptoms occurs in 5% to 30% of operated patients. The treatment of these recurrences primarily relies on conservative therapies, and in case of failure, surgical intervention, particularly neurolysis of the brachial plexus. In order to prevent a new recurrence, it is desirable to cover the neurolyzed brachial plexus with a flap, providing better local vascularization. However, fatty perforating flaps, by avoiding muscle harvesting, reduce donor site sequelae. We aim to investigate, through validated and recommended questionnaires, the impact of covering the neurolyzed brachial plexus with a free fatty flap after neurolysis in the context of recurrent neurological Thoraco-Brachial Outlet Syndrome.

Official Title
-----------------
Prospective Evaluation of Improvement in Pain and Quality of Life After Free Fat Flap for Treatment of Recurrent Neurological Thoracobrachial Outlet Syndrome

Conditions
-----------------
Neurogenic Thoracic Outlet Syndrome

Intervention / Treatment
-----------------
* Other: Free fat flap


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients underwent brachial plexus neurolysis and free fat flap coverage in the context of recurrence of neurological thoraco-brachial outlet syndrome Exclusion Criteria: Patients were unable to express their non-opposition to participating in the study. patients under guardianship or trusteeship. patients whose mother tongue is not French. patients who cannot read and/or write.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Free fat flap|Free fat flap In Recurrent neurogenic thoracic outlet syndrome Surgical Treatment|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluating the impact on pain of covering the brachial plexus with a free fat flap | the percentage reduction in pain assessed by a numerical scale from 0 to 10 | pre-op and six months post-op | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Recurrent neurogenic thoracic outlet syndrome, Free fat flap
Pharmacokinetics of Irbesartan/Amlodipine High FDC and Co-administration of Irbesartan and Amlodipine High in Healthy Volunteers

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare pharmacokinetics and safety of Irbesartan and Amlodipine High Fixed Dose Combination and coadministration of mono compounds in healthy adult volunteers

Official Title
-----------------
A Randomized, Open-label, Crossover, Phase 1 Study to Evaluate Pharmacokinetics and Safety of Irbesartan/Amlodipine High Fixed Dose Combination in Comparison With Co-administration of Mono Compounds in Healthy Volunteers

Conditions
-----------------
Healthy Volunteers

Intervention / Treatment
-----------------
* Drug: Irbesartan/Amlodipine High FDC
* Drug: Irbesartan
* Drug: Amlodipine High


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who are 19 years or older on screening Signed informed consent Healthy Volunteer Other inclusion applied Exclusion Criteria: Clinically relevant/significant findings as evaluated by the investigator Other exclusion applied

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Irbesartan/Amlodipine High Fixed dose combination<br>participants will receive one tablet of Irbesartan/Amlodipine High FDC in a crossover design | Drug: Irbesartan/Amlodipine High FDC<br>* Irbesartan/Amlodipine High FDC<br>|
| Other: Co-administration of Irbesartan and Amlodipine High<br>participants will receive one table each of Irbesartan and Amlodipine High in a crossover design | Drug: Irbesartan<br>* Co-administration of Irbesartan and Amlodipine High<br>Drug: Amlodipine High<br>* Co-administration of Irbesartan and Amlodipine High<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AUCt of Irbesartan and Amlodipne High |  | 72 hours | 
| Cmax Irbesartan and Amlodipne High |  | 72 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AUCinf of Irbesartan and Amlodipine High |  | 72 hours | 
| AUCt/AUCinf of Irbesartan and Amlodipine High |  | 72 hours | 
| tmax of Irbesartan and Amlodipine High |  | 72 hours | 
| half-life of Irbesartan and Amlodipine High |  | 72 hours | 
| CL/F of Irbesartan and Amlodipine High |  | 72 hours | 
| Vz/F of Irbesartan and Amlodipine High |  | 72 hours |